-
近年乳腺癌发病率增加的趋势逐年上升,患病人群也日益更趋于年轻化,成为严重危害女性健康及生存质量的重要因素[1-2]。D-二聚体(D-D)是血纤维蛋白的降解产物,其水平可反映纤溶活性,临床上常常作为诊断血栓性疾病的重要指标[3-4]。有研究发现D-D水平的显著升高,与肺癌、结直肠癌等恶性肿瘤之发生和恶化有关[5-7]。本文意在探讨乳腺良恶性病变病人血D-D水平有无差异以及乳腺癌不同临床分期、不同病理特征病人D-D水平的相关性,以期为临床对乳腺癌病人的诊断、病情进展和预后评估提供可能的临床证据。
-
恶性肿瘤组D-D值为(0.84±0.74)mg/L,大于良性病变组的(0.23±0.05)mg/L,差异有统计学意义(t=6.01, P < 0.01)。
-
有淋巴结转移者D-D水平高于无转移者(P < 0.05);TNM Ⅰ期与Ⅱ期D-D水平差异无统计学意义(P>0.05),Ⅲ期高于Ⅰ期和Ⅱ期(P < 0.05);Ki-67高表达D-D值高于低表达(P < 0.05),但低表达与中表达、中表达与高表达比较差异无统计学意义(P>0.05)。ER、PR、Her-2不同表达情况的D-D比较差异无统计学意义(P>0.05)(见表 1)。
临床病理特征 n D-D/(mg/L) F P MS组内 淋巴结转移 有
无21
331.12±0.80
0.67±0.662.26# < 0.05 — TNM分期 Ⅰ 13 0.43±0.34 5.15 < 0.01 0.476 Ⅱ 26 0.80±0.77 Ⅲ 15 1.26±0.76*# ER 阳性
阴性41
130.77±0.72
1.07±0.801.31# > 0.05 — PR 阳性
阴性35
190.80±0.74
0.91±0.760.50# > 0.05 — HER-2 阳性
阴性34
200.77±0.71
0.96±0.790.91# > 0.05 — Ki-67 低表达 14 0.51±0.34 3.54 < 0.05 0.499 中表达 8 0.56±0.39 高表达 32 1.05±0.86* 注:TNM分期Ⅱ与Ⅲ、Ki-67低表达与高表达比较*P < 0.05;TNM分期Ⅰ与Ⅲ比较#P < 0.01。#示t值 表 1 恶性肿瘤组病人血D-D水平与临床病理特征的关系
乳腺癌病人血D-二聚体水平与临床病理学特征的相关性
Correlation between serum D-dimer level and clinicopathological features in breast cancer patients
-
摘要:
目的探讨乳腺癌病人血D-二聚体(D-D)水平与其临床病理学特征的相关性,以期为临床对乳腺癌病人的诊断、病情进展和预后评估提供临床证据。 方法采用随机数字表法选取54例乳腺癌病人作为恶性肿瘤组,同法随机选取同期乳腺良性病变54例作为良性病变组。所有入组病人于入院时抽取静脉血检测血D-D;乳腺癌标本雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体(Her-2)和Ki-67表达情况来源于医院病理诊断报告。分析恶性肿瘤组和良性病变组病人血D-D水平的差异,并研究恶性肿瘤组乳腺癌病人血D-D水平与其临床病理特征的关系。 结果恶性肿瘤组D-D水平高于良性病变组(P < 0.01)。有淋巴结转移者D-D水平高于无转移者(P < 0.05);TNM Ⅰ期与Ⅱ期D-D水平差异无统计学意义(P>0.05),Ⅲ期D-D水平高于Ⅰ期和Ⅱ期(P < 0.05);Ki-67高表达D-D值高于低表达(P < 0.05),但低表达与中表达、中表达与高表达比较差异无统计学意义(P>0.05)。ER、PR、Her-2不同表达情况的D-D比较差异无统计学意义(P>0.05)。 结论D-D水平升高与乳腺癌TNM分期、淋巴结转移、Ki-67表达相关, 提示检测乳腺癌病人D-D水平可作为诊断、病情与预后评估的辅助指标之一。 Abstract:ObjectiveTo explore the correlation between blood D-dimer (D-D) level and clinicopathological characteristics of breast cancer patients, in order to provide possible clinical evidence for the diagnosis, disease progression and prognosis evaluation of breast cancer patients. MethodsFifty-four breast cancer patients were selected as the malignant tumor group by random number table method, and 54 patients with benign breast lesions during the same period were randomly selected as the benign lesion group.All patients were drawn with venous blood at the time of admission to the hospital to detect the level of D-D in the blood.The expression of ER, PR, Her-2 and Ki-67 in breast cancer specimens was obtained from the hospital pathological diagnosis report.The differences in the level of D-D between the malignant tumor group and the benign lesion group were analyzed, and the relationship between the level of D-D and their clinicopathological characteristics of breast cancer patients in malignant tumor group were studied. ResultsThe level of D-D in the malignant tumor group was significantly higher than that in the benign lesion group(P < 0.01).The D-D level in patients with lymph node metastasis was higher than that without metastasis (P < 0.05).There was no significant difference between the D-D level of the patients TNM stage Ⅰ and stage Ⅱ(P>0.05);stage Ⅲ was higher than stage Ⅰ and stage Ⅱ(P < 0.05).Ki-67 high-expression D-D values were higher than low-expression (P < 0.05), but there was no difference between low-expression and medium-expression, medium-expression and high-expression(P>0.05).There was no significant difference in the D-D level of different expressions of ER, PR and Her-2 in immunohistochemistry (P>0.05). ConclusionsThe elevated level of D-D is associated with breast cancer TNM stage, lymph node metastasis and Ki-67 expression.It is suggested that the detection of D-D level in breast cancer patients be used as one of the auxiliary indicators for diagnosis, condition and prognosis evaluation. -
Key words:
- breast neoplasms /
- D-dimer /
- TNM staging /
- lymph node metastasis
-
表 1 恶性肿瘤组病人血D-D水平与临床病理特征的关系
临床病理特征 n D-D/(mg/L) F P MS组内 淋巴结转移 有
无21
331.12±0.80
0.67±0.662.26# < 0.05 — TNM分期 Ⅰ 13 0.43±0.34 5.15 < 0.01 0.476 Ⅱ 26 0.80±0.77 Ⅲ 15 1.26±0.76*# ER 阳性
阴性41
130.77±0.72
1.07±0.801.31# > 0.05 — PR 阳性
阴性35
190.80±0.74
0.91±0.760.50# > 0.05 — HER-2 阳性
阴性34
200.77±0.71
0.96±0.790.91# > 0.05 — Ki-67 低表达 14 0.51±0.34 3.54 < 0.05 0.499 中表达 8 0.56±0.39 高表达 32 1.05±0.86* 注:TNM分期Ⅱ与Ⅲ、Ki-67低表达与高表达比较*P < 0.05;TNM分期Ⅰ与Ⅲ比较#P < 0.01。#示t值 -
[1] DESANTIS CE, MA J, GAUDET MM, et al. Breast cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(6): 438. doi: 10.3322/caac.21583 [2] CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115. doi: 10.3322/caac.21338 [3] 周平, 王亚倩, 李冰, 等. 不同分期肺癌患者术后下肢深静脉血栓形成发生率及凝血指标水平比较[J]. 中华实用诊断与治疗杂志, 2020, 34(1): 59. [4] JOHNSON ED, SCHELL JC, RODGERS GM. The D-dimer assay[J]. Am J Hematol, 2019, 94(7): 833. [5] TANAKA N, KIKUCHI E, MATSUMOTO K, et al. Prognostic value of plasma fibrinogen levels in patients with localized upper tract urothelial carcinoma[J]. BJU Int, 2013, 111(6): 857. doi: 10.1111/j.1464-410X.2012.11353.x [6] KILIC L, YILDIZ I, SEN FK, et al. D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients[J]. Cancer Biomark, 2015, 15(4): 405. doi: 10.3233/CBM-150477 [7] MI XK, LIU QR, ZHU L, et al. Mechanism of the high coagulation state of breast cancer tissue factor[J]. Eur Rev Med Pharmacol Sci, 2017, 21(9): 2167. [8] SUNG H, FERLAY J, SIEGEL RL, et al. Global Cancer Statistics 2020: GLOBO CAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209. doi: 10.3322/caac.21660 [9] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394. doi: 10.3322/caac.21492 [10] 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂, 2019, 41(1): 19. doi: 10.3760/cma.j.issn.0253-3766.2019.01.005 [11] 李江, 杨珂璐, 蔡依彤, 等. 全球乳腺癌筛查指南质量评价[J]. 中华流行病学杂, 2021, 42(2): 219. doi: 10.3760/cma.j.cn112338-20200806-01032 [12] BEVERS TB, HELVIE M, BONACCIO E, et al. Breast cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2018, 16(11): 1362. doi: 10.6004/jnccn.2018.0083 [13] SIU AL, U.S. Preventive Services Task Force. Screening for breast cancer: U.S. preventive services task force recommendation statement[J]. Ann Intern Med, 2016, 164(4): 279. doi: 10.7326/M15-2886 [14] 陈万青, 李霓, 石菊芳, 等. 中国城市癌症早诊早治项目进展[J]. 中国肿瘤, 2019, 28(1): 23. [15] 黄静, 杨湘红, 刘爱, 等. 农村地区妇女"两癌筛查"项目实施中的问题与对策[J]. 中国全科医学, 2020, 23(13): 1680. doi: 10.12114/j.issn.1007-9572.2019.00.509 [16] 李红, 李朋, 陈震. 乳腺癌发病危险因素的Meta分析[J]. 实用预防医学, 2014, 21(9): 109. [17] 戴琼, 杜玉开. 女性乳腺癌危险因素的Meta分析[J]. 中华疾病控制杂志, 20110, 14(6): 544. [18] GREENBERG CS. The role of D-dimer testing in clinical hematology and oncology[J]. Clin Adv Hematol Oncol, 2017, 15(8): 580. [19] WEITZ JI, FREDENBURGH JC, EIKELBOOM JW. A test in context: D-dimer[J]. J Am Coll Cardiol, 2017, 70(19): 2411. doi: 10.1016/j.jacc.2017.09.024 [20] TINHOLT M, SANDSET PM, MOWINCKEL MC, et al. Determinants of acquired activated protein C resistance and D-dimer in breast cancer[J]. Thromb Res, 2016, 145(1): 78. [21] CHAARI M, AYADI I, ROUSSEAUA, et al. Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability[J]. BMC Cancer, 2014, 14(1): 991. [22] 陈亮, 李兰丽, 林满遍. FDP、D-二聚体在恶性肿瘤血瘀证腹水患者预后中的意义[J]. 中医药临床杂志, 2018, 30(6): 1115. [23] 郭志唐, 邹仁超, 柯阳, 等. 肝细胞癌患者术前血浆纤维蛋白原和D-二聚体水平的临床分析[J]. 重庆医学, 2019(13): 2210. [24] 蒋凤莲, 杨伟洪, 黄文宇. 乳腺癌患者血浆D-二聚体水平与乳腺癌组织中Ki-67表达的相关性[J]. 中国实用医药, 2021, 16(13): 24. [25] 杨锦, 王倩荣, 张俊美, 等. 美国癌症联合会第8版分期系统对不同分子分型乳腺癌的分期评价及预后判断[J]. 肿瘤研究与临床, 2020, 32(8): 535. [26] KEY TJ, APPLEBY PN, REEVES GK, et al. Steroid hormone measurements from different types of assays in relation to body mass index and breast cancer risk in postmenopausal women: Reanalysis of eighteen prospective studies[J]. Steroids, 2015, 99(Pt A): 49. [27] CHOONG GM, CULLEN GD, O'SULLIVAN CC. Evolving standards of care and new challenges in the management of HER2-positive breast cancer[J]. CA Cancer J Clin, 2020, 70(5): 355. [28] 冯红蕾, 崔林, 李泽, 等. 乳腺癌患者血浆D-二聚体水平与临床病理特征的关系[J]. 山东医药, 2014, 54(42): 8. [29] DOWSETT M, NIELSEN TO, A'HERN R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group[J]. J Natl Cancer Inst, 2011, 103(22): 1656. [30] 杨文涛, 步宏. 乳腺癌雌、孕激素受体免疫组织化学检测指南[J]. 中华病理学杂志, 2015, 44(4): 237. [31] 杨壹羚, 郭晓静, 付丽. 乳腺癌主要分子病理指标检测结果的解读与分析[J]. 中华病理学杂志, 2020, 49(5): 526.